.jpeg)
2026-06-05 05:52:29
Tofacitinib is an oral JAK inhibitor that suppresses inflammation by blocking cytokine signaling pathways. It is approved for the treatment of various immune-mediated conditions including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
2026-06-05 05:46:25
Tucatinib, a highly selective HER2 tyrosine kinase inhibitor, is demonstrating key value in treating HER2-positive breast cancer with brain metastases and colorectal cancer. Its precise mechanism and favorable tolerability are advancing HER2-targeted therapy.
2026-06-04 03:40:01
This article systematically explains the acquired resistance phenomenon of Garsorasib, a KRAS G12C covalent inhibitor, and details common resistance mechanisms, standardized diagnostic procedures, individualized subsequent treatment strategies based on different resistance mechanisms, cutting-edge combination regimens and clinical trial opportunities, providing comprehensive reference for clinical management and patient treatment decisions.
2026-06-03 03:11:10
This article provides a detailed analysis of the oral BRAF inhibitor vemurafenib, explaining its mechanism of action against the BRAF V600E mutation, its central role in treating advanced melanoma, its potential in other rare conditions like Erdheim-Chester disease, and outlines its standard usage and key safety considerations.
2026-06-02 06:02:23
Vemurafenib is an oral targeted therapy that selectively inhibits the BRAF V600E mutant protein, offering a revolutionary treatment option for patients with specific types of melanoma and marking the era of "precision medicine" in oncology.
2026-05-29 07:46:00
A comprehensive analysis of the latest clinical data for the highly selective KRAS G12C inhibitor Garsorasib in NSCLC and solid tumors, covering first-line chemotherapy combinations, immunotherapy regimens, brain metastasis efficacy, and resistance management.
2026-05-27 02:05:59
Zongertinib (Hernexeos) gains FDA approval for HER2-mutated NSCLC, offering targeted therapy based on 76% response rate data, transforming treatment landscape.
2026-05-25 04:05:18
Explore the breakthrough of Sotorasib (AMG-510), the first approved KRAS G12C inhibitor. Detailed clinical trial data, dosage guidelines, and global pricing insights for patients in Hong Kong, Macau, and worldwide.
2026-05-22 04:06:55
LONSURF® (Trifluridine/Tipiracil) has become a cornerstone in the later-line treatment of metastatic colorectal cancer. This article explores its origins at Taiho Pharmaceutical, its unique mechanism of action, and the robust global manufacturing network ensuring its quality and availability.
2026-05-21 06:42:31
Eli Lilly announced FDA approval of Inluriyo (Imlunestrant), an oral estrogen receptor antagonist for ER+, HER2- advanced breast cancer with ESR1 mutations post-endocrine therapy progression.
2026-05-20 02:31:44
Explore the medicinal chemistry and clinical profile of Tivozanib. This guide covers its synthetic route, high selectivity for VEGFR, and role in targeted therapy for advanced kidney cancer.
2026-05-20 02:26:46
A comprehensive guide to Trifluridine/Tipiracil (FTD/TPI), an oral chemotherapy for metastatic colorectal and gastric cancers. Learn about safety profiles, bone marrow suppression, and clinical management strategies.
